Learn how Spring's technology is used to discover novel small-molecule adjuvants by applying our deep learning-based approach to high-dimensional phenotypic drug screens.

By using the Spring Engine to analyze a variety of cell types in a single experiment — in this case a heterogenous mixture of primary human PBMCs — Spring is able to quantify the immune response behavior of marketed reference adjuvants, directed agonists, and unknown compounds.